Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.86
CERS's Cash to Debt is ranked lower than
64% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CERS: 4.86 )
Ranked among companies with meaningful Cash to Debt only.
CERS' s Cash to Debt Range Over the Past 10 Years
Min: 0.62  Med: 100.50 Max: 14206.57
Current: 4.86
0.62
14206.57
Equity to Asset 0.65
CERS's Equity to Asset is ranked lower than
54% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CERS: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
CERS' s Equity to Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.68 Max: 0.9
Current: 0.65
0.06
0.9
F-Score: 2
Z-Score: 1.82
M-Score: -2.82
WACC vs ROIC
12.71%
-803.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -181.63
CERS's Operating margin (%) is ranked lower than
59% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. CERS: -181.63 )
Ranked among companies with meaningful Operating margin (%) only.
CERS' s Operating margin (%) Range Over the Past 10 Years
Min: -390.85  Med: -96.79 Max: -26.64
Current: -181.63
-390.85
-26.64
Net-margin (%) -185.20
CERS's Net-margin (%) is ranked lower than
59% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. CERS: -185.20 )
Ranked among companies with meaningful Net-margin (%) only.
CERS' s Net-margin (%) Range Over the Past 10 Years
Min: -410.21  Med: -107.85 Max: -13.43
Current: -185.2
-410.21
-13.43
ROE (%) -64.00
CERS's ROE (%) is ranked lower than
69% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CERS: -64.00 )
Ranked among companies with meaningful ROE (%) only.
CERS' s ROE (%) Range Over the Past 10 Years
Min: -140.02  Med: -81.39 Max: -7.02
Current: -64
-140.02
-7.02
ROA (%) -45.37
CERS's ROA (%) is ranked lower than
66% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CERS: -45.37 )
Ranked among companies with meaningful ROA (%) only.
CERS' s ROA (%) Range Over the Past 10 Years
Min: -65.51  Med: -46.60 Max: -5.48
Current: -45.37
-65.51
-5.48
ROC (Joel Greenblatt) (%) -960.09
CERS's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CERS: -960.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CERS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2927.5  Med: -855.21 Max: -495.08
Current: -960.09
-2927.5
-495.08
Revenue Growth (3Y)(%) -19.20
CERS's Revenue Growth (3Y)(%) is ranked lower than
72% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CERS: -19.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CERS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.5  Med: 4.85 Max: 52.4
Current: -19.2
-44.5
52.4
EBITDA Growth (3Y)(%) 30.40
CERS's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CERS: 30.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CERS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.8  Med: 10.55 Max: 36.4
Current: 30.4
-52.8
36.4
EPS Growth (3Y)(%) 25.80
CERS's EPS Growth (3Y)(%) is ranked higher than
80% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CERS: 25.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CERS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -61  Med: 2.00 Max: 57.1
Current: 25.8
-61
57.1
» CERS's 10-Y Financials

Financials (Next Earnings Date: 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CERS Guru Trades in Q2 2015

Ron Baron 150,000 sh (+12.44%)
PRIMECAP Management 7,400,000 sh (+1.37%)
Jim Simons Sold Out
Chuck Royce 2,801,305 sh (-10.94%)
» More
Q3 2015

CERS Guru Trades in Q3 2015

Ron Baron 175,000 sh (+16.67%)
PRIMECAP Management 7,500,000 sh (+1.35%)
Chuck Royce 2,245,405 sh (-19.84%)
» More
Q4 2015

CERS Guru Trades in Q4 2015

PRIMECAP Management 7,500,000 sh (unchged)
Ron Baron 110,000 sh (-37.14%)
Chuck Royce 1,199,100 sh (-46.60%)
» More
Q1 2016

CERS Guru Trades in Q1 2016

Jim Simons 18,600 sh (New)
PRIMECAP Management 7,800,000 sh (+4.00%)
Ron Baron 63,000 sh (-42.73%)
Chuck Royce 268,000 sh (-77.65%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:INO, NAS:NTLA, NAS:ANIP, OTCPK:GNFTF, NAS:INSM, NAS:CASC, NAS:ATRA, NAS:PACB, OTCPK:IPHYF, NAS:CORT, OTCPK:SNBIF, NAS:MACK, OTCPK:BIESF, NAS:ZIOP, NAS:DVAX, OTCPK:BPMUF, NAS:XNCR, NAS:ANIK, NAS:BPMC, NAS:PDLI » details
Traded in other countries:CU2.Germany,
Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 12 issued or allowed United States patents and approximately 87 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations' blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.

Guru Investment Theses on Cerus Corp

Baron Funds Comments on Cerus Corp - Feb 25, 2016

Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cerus Corp

Baron Funds Comments on Cerus Corp Guru stock highlight
Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years. Read more...

Ratios

vs
industry
vs
history
P/B 7.81
CERS's P/B is ranked lower than
79% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CERS: 7.81 )
Ranked among companies with meaningful P/B only.
CERS' s P/B Range Over the Past 10 Years
Min: 0.81  Med: 6.18 Max: 55
Current: 7.81
0.81
55
P/S 18.72
CERS's P/S is ranked lower than
60% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. CERS: 18.72 )
Ranked among companies with meaningful P/S only.
CERS' s P/S Range Over the Past 10 Years
Min: 1.22  Med: 6.91 Max: 18.95
Current: 18.72
1.22
18.95
Current Ratio 5.23
CERS's Current Ratio is ranked higher than
55% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CERS: 5.23 )
Ranked among companies with meaningful Current Ratio only.
CERS' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.98 Max: 9.96
Current: 5.23
1.03
9.96
Quick Ratio 4.74
CERS's Quick Ratio is ranked higher than
54% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CERS: 4.74 )
Ranked among companies with meaningful Quick Ratio only.
CERS' s Quick Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.65 Max: 9.96
Current: 4.74
1.03
9.96
Days Inventory 205.23
CERS's Days Inventory is ranked lower than
71% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. CERS: 205.23 )
Ranked among companies with meaningful Days Inventory only.
CERS' s Days Inventory Range Over the Past 10 Years
Min: 122.1  Med: 212.05 Max: 343.01
Current: 205.23
122.1
343.01
Days Sales Outstanding 43.66
CERS's Days Sales Outstanding is ranked higher than
66% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. CERS: 43.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.09  Med: 64.57 Max: 256.86
Current: 43.66
44.09
256.86
Days Payable 98.94
CERS's Days Payable is ranked higher than
66% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. CERS: 98.94 )
Ranked among companies with meaningful Days Payable only.
CERS' s Days Payable Range Over the Past 10 Years
Min: 81.15  Med: 127.78 Max: 1578.67
Current: 98.94
81.15
1578.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.63
CERS's Price/Net Cash is ranked lower than
75% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. CERS: 12.63 )
Ranked among companies with meaningful Price/Net Cash only.
CERS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.88  Med: 6.77 Max: 103.13
Current: 12.63
1.88
103.13
Price/Net Current Asset Value 8.64
CERS's Price/Net Current Asset Value is ranked lower than
69% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. CERS: 8.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CERS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.17  Med: 7.26 Max: 370.83
Current: 8.64
1.17
370.83
Price/Tangible Book 8.02
CERS's Price/Tangible Book is ranked lower than
73% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CERS: 8.02 )
Ranked among companies with meaningful Price/Tangible Book only.
CERS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.92  Med: 6.77 Max: 250
Current: 8.02
0.92
250
Price/Median PS Value 2.71
CERS's Price/Median PS Value is ranked lower than
87% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CERS: 2.71 )
Ranked among companies with meaningful Price/Median PS Value only.
CERS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.32 Max: 75.25
Current: 2.71
0.2
75.25
Earnings Yield (Greenblatt) (%) -10.80
CERS's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CERS: -10.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CERS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.76  Med: 295.10 Max: 2848.7
Current: -10.8
-18.76
2848.7

More Statistics

Revenue (TTM) (Mil) $34.16
EPS (TTM) $ -0.66
Beta1.49
Short Percentage of Float18.12%
52-Week Range $4.27 - 6.89
Shares Outstanding (Mil)101.71

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 58 84
EPS ($) -0.66 -0.52 -0.36
EPS w/o NRI ($) -0.66 -0.52 -0.36
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CERS

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Cerus Corp Feb 25 2016 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Cerus to Release Second Quarter 2016 Results on August 4, 2016 Jul 21 2016
Why These Stocks Are Gaining Ground on Tuesday? Jul 19 2016
Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood... Jul 11 2016
Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood... Jul 11 2016
5 Analyst Stock Picks Under $10 With Massive Upside Calls Jul 10 2016
CORRECTING and REPLACING Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference... Jul 08 2016
CORRECTING and REPLACING Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference... Jul 08 2016
Cerus and CEI Announce Donation of INTERCEPT Blood System Kits to HEMORIO for Emergency Preparedness... Jul 06 2016
Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13, 2016 Jul 05 2016
Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13, 2016 Jul 05 2016
Cerus Corporation, the Transfusion Service of the Swiss Red Cross, and the University Hospital of... Jun 30 2016
Cerus Corp. – Value Analysis (NASDAQ:CERS) : June 21, 2016 Jun 21 2016
Why Anthem, Cigna, Fiat Chrysler, and Two Other Stocks Are Trending Today Jun 20 2016
Cerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : June 20, 2016 Jun 20 2016
Cerus Announces Agreement with BARDA for Potential Funding of up to approximately $180 million to... Jun 19 2016
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to... Jun 19 2016
CERUS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2016
ETF’s with exposure to Cerus Corp. : June 8, 2016 Jun 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)